Carmine DeNardo is a seasoned healthcare executive with a distinguished record of building, scaling, and leading high‑growth pharmacy services organizations. He brings deep expertise across specialty pharmacy, 340B TPA services, home infusion, health‑system pharmacy managed services, pharmacy hub services, and retail pharmacy—supported by a disciplined focus on operational excellence, revenue acceleration, and margin expansion.

Before joining Medix Infusion, Carmine served as Vice President and General Manager of Omnicell’s Specialty Pharmacy Division, where he led the integration and expansion of ReCept Pharmacy. Under his leadership, the business delivered strong year‑over‑year growth and introduced innovative service offerings that generated substantial recurring revenue.

Previously, as CEO and President of ReCept Pharmacy, Carmine transformed the organization from a regional provider into a national market leader. He scaled revenue from $32 million to more than $600 million and guided the company through a successful private equity investment and subsequent acquisition by Omnicell.

During his tenure at CVS Health, DeNardo helped launch and scale the PharmaCare Specialty Pharmacy business, growing it into a nationally recognized specialty pharmacy with a presence across multiple markets. He consistently delivered double‑digit EBITDA growth by securing strategic payer and manufacturer partnerships that broadened access to high‑cost therapies. DeNardo also built the operational and technology infrastructure required to support sustained national expansion and long‑term performance.

Carmine is known for aligning cross‑functional teams, executing disciplined growth strategies, and building scalable, high‑performing organizations. He is deeply committed to fostering a culture of collaboration, accountability, and excellence—believing that strong culture is foundational to long‑term success.

He is a respected industry leader and has served as Chairman of the Board for the National Association of Specialty Pharmacy.